177 related articles for article (PubMed ID: 23212544)
1. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment.
Martini G; Mignarri A; Ruvio M; Valenti R; Franci B; Del Puppo M; Federico A; Nuti R; Dotti MT
Calcif Tissue Int; 2013 Mar; 92(3):282-6. PubMed ID: 23212544
[TBL] [Abstract][Full Text] [Related]
2. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
[TBL] [Abstract][Full Text] [Related]
3. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.
Amador MDM; Masingue M; Debs R; Lamari F; Perlbarg V; Roze E; Degos B; Mochel F
J Inherit Metab Dis; 2018 Sep; 41(5):799-807. PubMed ID: 29560583
[TBL] [Abstract][Full Text] [Related]
4. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
Verrips A; Wevers RA; Van Engelen BG; Keyser A; Wolthers BG; Barkhof F; Stalenhoef A; De Graaf R; Janssen-Zijlstra F; Van Spreeken A; Gabreëls FJ
Metabolism; 1999 Feb; 48(2):233-8. PubMed ID: 10024088
[TBL] [Abstract][Full Text] [Related]
5. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.
Catarino CB; Vollmar C; Küpper C; Seelos K; Gallenmüller C; Bartkiewicz J; Biskup S; Hörtnagel K; Klopstock T
J Neurol; 2018 Feb; 265(2):388-393. PubMed ID: 29260356
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
Mignarri A; Magni A; Del Puppo M; Gallus GN; Björkhem I; Federico A; Dotti MT
J Inherit Metab Dis; 2016 Jan; 39(1):75-83. PubMed ID: 26153518
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis.
Mignarri A; Rossi S; Ballerini M; Gallus GN; Del Puppo M; Galluzzi P; Federico A; Dotti MT
J Neurol; 2011 May; 258(5):783-90. PubMed ID: 21104094
[TBL] [Abstract][Full Text] [Related]
8. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
Weissfeld T; Ratliff J
J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
[TBL] [Abstract][Full Text] [Related]
9. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.
Mandia D; Chaussenot A; Besson G; Lamari F; Castelnovo G; Curot J; Duval F; Giral P; Lecerf JM; Roland D; Pierdet H; Douillard C; Nadjar Y
J Neurol; 2019 Aug; 266(8):2043-2050. PubMed ID: 31115677
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Huidekoper HH; Vaz FM; Verrips A; Bosch AM
Eur J Pediatr; 2016 Jan; 175(1):143-6. PubMed ID: 26156051
[TBL] [Abstract][Full Text] [Related]
12. Failure in the treatment of long-standing osteoporosis in cerebrotendinous xanthomatosis.
Chang WN; Lui CC
J Formos Med Assoc; 1997 Mar; 96(3):225-7. PubMed ID: 9080765
[TBL] [Abstract][Full Text] [Related]
13. Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis.
van Heijst AF; Wevers RA; Tangerman A; Cruysberg JR; Renier WO; Tolboom JJ
Acta Paediatr; 1996 Aug; 85(8):932-6. PubMed ID: 8863874
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G; Steiner RD
J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
[TBL] [Abstract][Full Text] [Related]
15. Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study.
Isenhardt K; Schmitt R; Nagel A; Drach L; Schlote W
Clin Neuropathol; 2005; 24(6):276-83. PubMed ID: 16320823
[TBL] [Abstract][Full Text] [Related]
16. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.
Yahalom G; Tsabari R; Molshatzki N; Ephraty L; Cohen H; Hassin-Baer S
Clin Neuropharmacol; 2013; 36(3):78-83. PubMed ID: 23673909
[TBL] [Abstract][Full Text] [Related]
17. Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols.
DeBarber AE; Schaefer EJ; Do J; Ray JW; Larson A; Redder S; Fowler M; Duell PB
J Clin Lipidol; 2024; 18(3):e465-e476. PubMed ID: 38637260
[TBL] [Abstract][Full Text] [Related]
18. Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report.
Koyama S; Okabe Y; Suzuki Y; Igari R; Sato H; Iseki C; Tanji K; Suzuki K; Ohta Y
BMC Neurol; 2022 May; 22(1):193. PubMed ID: 35614401
[TBL] [Abstract][Full Text] [Related]
19. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
Dotti MT; Lütjohann D; von Bergmann K; Federico A
Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
[TBL] [Abstract][Full Text] [Related]
20. Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis.
Stelten BML; Bonnot O; Huidekoper HH; van Spronsen FJ; van Hasselt PM; Kluijtmans LAJ; Wevers RA; Verrips A
J Inherit Metab Dis; 2018 Jul; 41(4):641-646. PubMed ID: 28894950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
